Skip to main content

MELAS

2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Tisento Therapeutics
Tisento TherapeuticsMA - Cambridge
1 program
1
IW-6463 TabletsPhase 21 trial
Active Trials
NCT04475549Terminated8Est. Jan 2022
Khondrion
KhondrionNetherlands - Nijmegen
1 program
1
KH176Phase 11 trial
Active Trials
NCT02544217Completed32Est. Oct 2015

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Tisento TherapeuticsIW-6463 Tablets
KhondrionKH176

Clinical Trials (2)

Total enrollment: 40 patients across 2 trials

Phase 2a Study of IW-6463 in Adults Diagnosed With Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS)

Start: Nov 2020Est. completion: Jan 20228 patients
Phase 2Terminated

A Dose-escalating Clinical Trial With KH176

Start: May 2015Est. completion: Oct 201532 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.